welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
enrolling by invitation
A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Patients With Duchenne Muscular Dystrophy
study id #: NCT03985878
condition: Duchenne Muscular Dystrophy
status: enrolling by invitation
purpose:The purpose of this extension study is to evaluate the ongoing safety and tolerability of additional treatment with eteplirsen administered once weekly by intravenous (IV) infusion in male DMD patients who have successfully completed the 96-week eteplirsen study: Study 4658-102 (NCT03218995)
intervention: Eteplirsen
mechanism of action: Exon-skipping to promote dystrophin production
results: https://clinicaltrials.gov/ct2/show/results/NCT03985878
last updated: April 19, 2020
study details
study contacts
rareRelated
-
ICER Releases Draft Evidence Report on Treatments for Duchenne Muscular DystrophyThe Institute for Clinical and Economic ...
-
Study of Eteplirsen in DMD PatientsThe main objective of this study is to p...
-
A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of Casimersen, Eteplirsen and Golodirsen in Subject...This is an 48-week open-label study to d...
-
Long-Term Treatment With Eteplirsen in Nonambulatory Patients With Duchenne Muscular DystrophyThis analysis aims to describe the outco...
-
Insurers battle families over costly drug for fatal diseaseNolan and Jack Willis, twins from upstat...
-
Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular DystrophyThe primary objective of this study is t...
-
Study of Eteplirsen in Young Patients With DMD Amenable to Exon 51 SkippingThis is a multicenter, open-label, dose-...
-
Results at 96 Weeks of a Phase IIb Extension Study of the Exon-Skipping Drug Eteplirsen in Patients with Duchenne Mu...Objective: The objective of this study ...
-
Eteplirsen is Granted Accelerated Approval in UShttps://www.youtube.com/watch?v=Orig6mpu...
